COMPANY
Arsenal Medical, Inc.
Funding and NIH signals
- NIH award NIH awarded $2.24M (SBIR commercialization 1SB1AG102149-01, new, notice Sep 18, 2026). NIH RePORTER 1SB1AG102149-01 (Sep 18, 2026)
Evidence (1 event)
- Sep 18, 2026 · NIH RePORTER 1SB1AG102149-01
Organization: ARSENAL MEDICAL, INC.; City/State: Waltham, MA; Project number: 1SB1AG102149-01; Activity code: SB1; Fiscal year: 2026; Award notice date: 2026-09-18; FY total cost (award amount): 2238626; Administering IC: National Institute on Aging; Project title: RADIANT: A Pivotal Clinical Study of a Next-Generation Embolic for Chronic Subdural Hematoma; Organization type: Domestic For-Profits
- Sep 18, 2026 · NIH RePORTER 1SB1AG102149-01
Timeline
- Grant Government grant — SBIR: $2.24M (annual award, as published), announced Sep 18, 2026. Agency: NIH/NIA. Source: government award database. source ↗
- Trial start Not phased (device or behavioral study): MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma source ↗
- Trial start Not phased (device or behavioral study): REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam source ↗
- Grant Government grant — SBIR: $314,363 (annual award, as published), announced Jul 30, 2025. Agency: NIH/NINDS. Source: government award database. source ↗
Upcoming milestones
- Oct 31, 2026 (ESTIMATED) · Not phased · REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam · NCT02880163
- 2028-01 (ESTIMATED) · Not phased · MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma · NCT07541404
Funding
Clinical trials (lead sponsor) 2
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07541404 | MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma | Not phased (device or behavioral study) | Recruiting | Aug 13, 2026 | 2028-01 (estimated) |
| NCT02880163 | REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam | Not phased (device or behavioral study) | Recruiting | Aug 7, 2025 | Oct 31, 2026 (estimated) |
NIH awards 6
- NIH award 5R44CA257802-02 FY2022: $1,117,374 awarded for that fiscal year; activity R44 (SBIR); PI PHAM, QUYNH P; recipient as written: ARSENAL MEDICAL, INC., Waltham, MA. Flow Responsive Embolic Agent for the Comple source ↗
- NIH award 1R44CA257802-01A1 FY2021: $791,378 awarded for that fiscal year; activity R44 (SBIR); PI PHAM, QUYNH P; recipient as written: ARSENAL MEDICAL, INC., Waltham, MA. Flow Responsive Embolic Agent for the Comple source ↗
- NIH award 1R43HL154865-01 FY2020: $367,201 awarded for that fiscal year; activity R43 (SBIR); PI PHAM, QUYNH P; recipient as written: ARSENAL MEDICAL, INC., Waltham, MA. Ideal Embolic for Portal Vein Embolization source ↗
- NIH award 5R44GM117849-03 FY2018: $762,094 awarded for that fiscal year; activity R44 (SBIR); PI PHAM, QUYNH P; recipient as written: ARSENAL MEDICAL, INC., Waltham, MA. Development of Self-Expanding Foams for Percut source ↗
- NIH award 4R44GM117849-02 FY2017: $762,094 awarded for that fiscal year; activity R44 (SBIR); PI SHARMA, UPMA; recipient as written: ARSENAL MEDICAL, INC., Waltham, MA. Development of Self-Expanding Foams for Percuta source ↗
- NIH award 1R44GM117849-01 FY2016: $227,667 awarded for that fiscal year; activity R44 (SBIR); PI SHARMA, UPMA; recipient as written: ARSENAL MEDICAL, INC., Waltham, MA. Development of Self-Expanding Foams for Percuta source ↗